Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Management to Address Bear Stearns Healthcare Conference
WILMINGTON, Mass., Sep 12, 2002 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) announced today that Chairman, President and CEO James C. Foster and Senior Vice President and CFO Thomas F. Ackerman will discuss the company's business outlook at the Bear Stearns 15th Annual Healthcare Conference in New York. Company management will present on Wednesday, September 18, 2002, at 3:00 p.m. EDT.

A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River Laboratories website, http://www.criver.com. A webcast replay will be accessible through the Investor Relations section of the company's website approximately two hours following the presentation and will remain available until Tuesday, September 24, 2002. The associated slide presentation will be available for downloading during that time.

Charles River Laboratories, based in Wilmington, Massachusetts, is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. The Company is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies. The Company also offers a broad and growing portfolio of biomedical products and services that enable customers to reduce cost, increase speed, and enhance productivity and effectiveness in drug discovery and development. Charles River's customer base spans over 50 countries, and includes all of the major pharmaceutical and biotechnology companies, as well as many leading hospitals and academic institutions. The Company operates 78 facilities in 16 countries worldwide. For more information, visit the Company's web site as http://www.criver.com.

Caution Concerning Forward-Looking Statements: This document includes certain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations, and involve a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the forward looking statements, including acquisition integration risks, special interest groups, contaminations, industry trends, new displacement technologies, outsourcing trends, USDA and FDA regulation, changes in law, continued availability of products and supplies, personnel and control, and others that are described in more detail in the Risk Factors contained in the Company's most recent SEC filings. The Company disclaims any intent or obligation to update forward looking statements, and otherwise claims the safe harbor protections for forward looking statements afforded under The Private Securities Litigation Reform Act of 1995.

\CONTACT:
Charles River Laboratories (Investor Relations)
Susan E. Hardy, 978/658-6000 ext.1616
Director, Investor Relations
or
Charles River Laboratories (Media Relations)
Christopher DiFrancesco, 978/658-6000 ext.1508
Director, Corporate Communications

Copyright (C) 2002 Business Wire. All rights reserved.

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)